Daclatasvir-Based HCV Therapy in Patients with Advanced Cirrhosis or Post-Transplant HCV Recurrence

Rates of sustained virologic response were high in all subgroups, except patients with Child–Pugh class C cirrhosis.

Sofosbuvir–ledipasvir plus ribavirin has been shown effective for treating hepatitis C virus (HCV) infection in patients with decompensated cirrhosis, before or after liver transplantation (NEJM JW Gastroenterol Oct 2015 and Gastroenterology 2015; 149:649). Researchers have now conducted an industry-funded, prospective, phase 3, open-label study of 12 weeks of once-daily daclatasvir (60 mg) plus sofosbuvir (400 mg) and ribavirin (600 mg, with possible titration to 1000 mg) in two cohorts of HCV treatment-naive or -experienced patients with any HCV genotype (76% type 1):

60 patients with HCV-related cirrhosis (12 Child-Pugh class A, 32 class B, 16 class C), 6 with hepatocellular carcinoma (within Milan criteria), who were being considered for…

Reviewing Author

Atif Zaman, MD, MPH

Disclosures

Nothing to disclose

Atif Zaman, MD, MPH

Disclosures

Nothing to disclose

Daclatasvir-Based HCV Therapy in Patients with Advanced Cirrhosis or Post-Transplant HCV Recurrence

Topics

Reviewing Author